SPK004
BK virus (BKV) reactivation and nephropathy in kidney transplant recipients
Pre-clinicalActive
Key Facts
Indication
BK virus (BKV) reactivation and nephropathy in kidney transplant recipients
Phase
Pre-clinical
Status
Active
Company
About SpikImm
SpikImm is a clinical-stage biotech developing novel antibody therapies for viral infections in immunocompromised patients. The company's primary focus is its lead candidate, SPK004, a monoclonal antibody designed to prevent and treat BK virus nephropathy (BKVN) in kidney transplant recipients, a condition that can lead to graft loss. Operating as a private, pre-revenue entity, SpikImm is advancing its program through clinical development to address a significant complication in transplant medicine. Its approach aims to provide a targeted therapeutic option that could improve transplant outcomes without broadly compromising the patient's necessary immunosuppression.
View full company profile